

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**VOLUNTARY ANNOUNCEMENT  
PRE-APPLICATION FOR MARKETING REGISTRATION FOR  
13-VALENT PNEUMONIA CONJUGATE VACCINE SUBMITTED**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on 29 February 2024, the Group has submitted the pre-application for marketing registration for its 13-valent pneumonia conjugate vaccine, and plans to officially complete the application for marketing this year.

The 13-valent pneumonia conjugate vaccine is mainly used in infants and children aged 6 weeks to 5 years old to prevent invasive diseases caused by 13 pneumonia serotypes (including bacteremia pneumonia, meningitis, septicemia and bacteremia) included in the vaccine. Pneumonia disease is the main cause of illness and death in children under the age of 5. The World Health Organization (the “**WHO**”) listed children’s pneumonia diseases as diseases that require high priority use of vaccines for prevention, and recommended the use of 13-valent pneumonia conjugate vaccine for vaccination. In the WHO’s classification for vaccine-preventable diseases, pneumonia series products are at the “extremely high priority” level. Therefore, the 13-valent pneumonia conjugate vaccine has a huge market prospect and will be in short supply after its launch. The construction of the Group’s pneumonia series vaccine GMP workshop has been completed to meet international standards. The Phase III clinical samples of the 13-valent pneumonia conjugate vaccine are all produced in the standardized workshop.

By order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director  
and Chief Executive Officer*

Hong Kong, March 1, 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*